Notifications
Clear all
Topic starter
January 27, 2025 11:59 am
Please note that FOLFIRINOX is now considered high emetic risk and should be abstracted as such. In previous rounds, it was moderate emetic risk, however this changed at the start of round 1 2025. This change is reflected on the current Emetic Risk Chemo vs Immunotherapy Document. If you do not have a copy of this document, it can be found along the right side of this screen under Round 1 2025 Documents.
